India's menopause treatment industry is expected to grow at a CAGR of 6.6% through 2034. The industry is predicted to increase from USD 78.0 million in 2024 to USD 147.3 million by 2034. The menopause treatment industry in India was valued at USD 72.7 million in 2023 and is anticipated to exhibit a y-o-y growth of 7.2% in 2024.
| Attributes | Key Insights |
|---|---|
| Base Value (2023) | USD 72.7 million |
| Estimated India Menopause Treatment Industry Size (2024) | USD 78.0 million |
| Value of the Menopause Treatment in India (2034) | USD 147.3 million |
| Value-based CAGR (2024 to 2034) | 6.6% |
Increasing public awareness of menopause treatment’s benefits and growing prevalence of menopausal symptoms are the factors pushing the industry expansion. The menopause treatment industry in India is undergoing a transformative shift, marked by a growing acceptance of hormone replacement therapy (HRT) among women. This trend reflects individual health choices and presents a substantial industry opportunity.
Ongoing clinical trials in India signify a commitment to innovative solutions in the menopause treatment industry. The influx of treatments addresses current industry needs and propels the industry's growth, creating a competitive landscape and stimulating further innovations.
Increasing healthcare infrastructure and growing emphasis on women's health are expected to further surge the menopause treatment industry. The menopause therapy industry in India is expected to rise due to increasing demand for personalized medicine, which tailors treatment to each patient's unique issues.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
India's menopause treatment industry recorded a historical CAGR of 5.8% from 2019 to 2023. The industry value for India's menopause treatment reached USD 68.1 million in 2022 from USD 54.8 million in 2018.
During 2019 and 2023, there has been a significant shift in societal attitudes toward menopause, leading to increased awareness. Efforts by organizations and healthcare professionals to educate women about menopause have contributed to growth of the menopause treatment industry.
Supportive policies and initiatives from government bodies and healthcare organizations have augmenting a conducive environment for the development of menopause treatment. These measures include funding for research, awareness campaigns, and inclusion of menopausal health in public health programs.
Looking forward, the future of the menopause treatment industry anticipates a gradual acceleration of growth. Continued research & development efforts are expected to yield personalized and more effective treatments while integrating digital health and telemedicine is poised to enhance accessibility.
Increasing aging population contributes to sustained industry growth, with an increasing number of women entering menopause in India. Furthermore, the trend toward consumer empowerment and informed decision-making is likely to shape the industry by creating diverse treatment options.
These historic and futuristic factors create a dynamic landscape, offering opportunities for pharmaceutical companies, healthcare providers, and researchers to contribute to women's health during the menopausal transition.
A significant opportunity for expansion of the menopause drug industry lies in the notable increase in the number of menopausal drugs advancing through drug development pipelines of key manufacturers. This surge in research and development efforts signifies a promising trajectory for the industry.
The influx of innovative treatments not only addresses the current unmet needs in the industry but also supports a competitive landscape, stimulating further innovations in the menopause treatment industry. Increasing momentum in drug development activities represents a key catalyst for the growth and evolution of the menopause drug industry in India.
Exploring and advancing natural or herbal treatment options for menopausal symptoms is set to create opportunities for leading companies in the drug sector. This avenue of development holds the promise of providing therapeutic alternatives with fewer side effects, catering to increasing demand for more holistic and gentle approaches to menopause management.
The ‘organic’ trend also aligns with a broader cultural shift toward wellness and preventive healthcare, where consumers are increasingly inclined to explore alternative and natural remedies. Leading manufacturers in the menopausal pharmaceutical drugs sector are using this opportunity to develop evidence-based, scientifically validated natural treatments, ensuring safety and efficacy.
Principal Consultant
The prominence of traditional medicines like Shatavari and Ashwagandha, coupled with the availability of Ayurvedic treatment options, has posed a formidable challenge to growth of prescription (Rx) and over-the-counter (OTC) drugs for menopause treatment.
These herbal remedies, deeply rooted in Ayurveda, have gained substantial popularity among women seeking alternative and holistic approaches to manage menopausal symptoms.
Ayurvedic treatments, often perceived as natural and with fewer side effects, are increasingly preferred by those who may be wary of the potential risks associated with conventional hormonal therapies. This shift in consumer preferences toward traditional medicines poses a dual challenge for the Rx and OTC menopause drug industry.
The shift is expected to diminish the share of pharmaceutical menopause treatments as women explore alternative options deeply ingrained in Indian cultural practices. Furthermore, the perception of herbal remedies as safer and more aligned with holistic well-being influences women to opt for Ayurvedic alternatives. It helps in potentially reducing the demand for prescription and over-the-counter menopause drugs.
The table below shows the estimated growth rates of leading countries. Northern India, Northeast India, and Western India are set to record high CAGRs of 7.2%, 8.6%, and 7.8% respectively, through 2034.
| Region | Value CAGR (2024 to 2034) |
|---|---|
| Northern India | 7.2% |
| Northeast India | 8.6% |
| Central India | 5.3% |
| Eastern India | 5.0% |
| Western India | 7.8% |
| Southern India | 6.3% |
Southern India dominates the industry with a 31.4% share in 2023 and is projected to continue experiencing stable growth throughout the forecast period. Southern India hosts research and development hubs, contributing to the innovation in menopause treatments. Collaborations between pharmaceutical companies, research institutions, and healthcare providers lead to the introduction of novel therapeutic options, propelling industry growth.
Cultural shifts in Southern India have witnessed more open conversations about women's health, including menopause. This cultural change has increased awareness and a willingness to explore treatment options, positively impacting the menopause treatment industry.
Western India takes center stage in the menopause treatment industry, claiming a noteworthy industry share of 20.0%. Rapid urbanization and lifestyle changes in Western India have led to an increased prevalence of menopausal symptoms. Demand for effective treatment options is surging as women in urban areas are more aware and proactive about managing their health during the menopausal transition.
The relatively higher socioeconomic status of individuals in Western India allows for increased affordability and access to advanced menopause treatments. This economic stability contributes to a higher adoption rate of hormone replacement therapies and other specialized interventions.
In 2023, Eastern India held a significant industry share of 18.2%, asserting its dominance, and is anticipated to maintain robust growth over the forecast period. Growth of the menopause treatment industry in Eastern India is influenced by the region's rising healthcare infrastructure. Improved access to healthcare facilities and specialized clinics catering to menopausal health contributes to heightened awareness and treatment options in Eastern India.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below shows the hormone therapy segment leading in terms of product. It is estimated to thrive at a 7.4% CAGR between 2024 and 2034. Based on route of administration, the oral segment is anticipated to hold a dominant share through 2034. It is set to exhibit a CAGR of 7.3% during the forecast period.
| Products | Value CAGR (2024 to 2034) |
|---|---|
| Hormone Therapy | 7.4% |
| Non-Hormonal Therapy | 6.1% |
| Nutritional Supplements | 1.9% |
Hormone therapy dominated the industry with a 55.8% share in 2023 and is projected to continue experiencing high growth throughout the forecast period. Hormone therapy dominates the menopause industry by providing effective relief from symptoms like hot flashes and mood swings.
Hormone therapy addresses hormonal imbalances, making it a preferred choice among women seeking comprehensive and targeted solutions during the menopausal transition, thereby augmenting its widespread adoption.
| Route of Administration | Value CAGR (2024 to 2034) |
|---|---|
| Topical | 6.0% |
| Injectable | 4.4% |
| Oral | 7.3% |
The oral segment held 64.2% industry share in 2023 and is projected to continue experiencing steady growth throughout the forecast period. Oral medications lead the industry due to their convenience and ease of administration.
Women prefer oral formulations for hormone replacement therapy, contributing to high patient adherence. The simplicity and familiarity of oral intake make it a prominent and accessible choice in the menopause treatment landscape.
| Market Status | Value CAGR (2024 to 2034) |
|---|---|
| Rx | 6.8% |
| OTC | 4.4% |
Based on market status, the Rx segment held 94.2% industry share in 2023. Prescription medications play a pivotal role in shaping the menopause industry, ensuring that treatment plans are tailored to individual needs.
The expertise of healthcare professionals prescribing specific medications addresses diverse symptom profiles, offering personalized solutions. This approach establishes prescription medications as key drivers in the menopause treatment sector.
| Distribution Channel | Value CAGR (2024 to 2034) |
|---|---|
| Hospitals | 6.5% |
| Specialty Clinics | 8.0% |
| Online Sales/Online Pharmacy Platforms | 9.4% |
Hospitals will likely dominate the industry with a 43.2% share in 2023. Hospitals are at the forefront of menopause treatment, offering comprehensive healthcare services in India.
Specialized menopause clinics within hospitals provide a multidisciplinary approach, combining medical expertise, counseling, and supportive care. The institutional infrastructure and accessibility make hospitals central to effectively managing menopausal symptoms in India.
In the dynamic landscape of the menopause treatment industry, companies are strategically emphasizing collaboration & partnerships and continuously focusing on product approval. These initiatives reflect the industry's commitment to innovation, addressing evolving industry demands, and staying competitive. Instances of key developmental strategies by industry players in India’s menopause treatment industry are given below:
India's industry is set to reach USD 78.0 million in 2024.
Demand in India is slated to rise at a 6.6% CAGR through 2034.
The target industry is set to reach USD 147.3 million in 2034.
Hormone therapy segment is expected to garner a significant value share by 2024.
India’s menopause treatment industry was valued at USD 72.7 million in 2023.
1. Executive Summary 2. Industry Overview 3. Key Trends 4. Value Added Insights 5. Industry Background 6. Industry Demand (in Value or Size in USD million) Analysis 2019 to 2023 and Forecast, 2024 to 2034 7. Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product 7.1. Hormone Therapy 7.1.1. Combination 7.1.2. Tibolone 7.1.3. Progestin-only Medicines 7.1.4. Estrogen-only Medicines 7.2. Non-hormonal Therapy 7.2.1. Gabapentinoids 7.2.2. Serotonin-norepinephrine Reuptake Inhibitors (SNRI) 7.2.3. Selective Serotonin Reuptake Inhibitors (SSRI) 7.2.4. Others 7.3. Nutritional Supplements 7.3.1. Multi-vitamin Supplements 7.3.2. Phytoestrogen Supplement 7.3.3. Antioxidant Supplements 7.3.4. Other Supplements 8. Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration 8.1. Topical 8.2. Injectable 8.3. Oral 9. Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, By Market Status 9.1. Rx 9.2. OTC 10. Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 10.1. Hospitals 10.2. Specialty Clinics 10.3. Retail Pharmacies 10.4. Drug Stores 10.5. Online Sales/Online Pharmacy Platforms 11. Industry Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 11.1. Northern India 11.2. Northeast India 11.3. Central India 11.4. Eastern India 11.5. Western India 11.6. Southern India 12. Northern Industry Analysis 2019 to 2023 and Forecast 2024 to 2034 13. Northeast Industry Analysis 2019 to 2023 and Forecast 2024 to 2034 14. Central Industry Analysis 2019 to 2023 and Forecast 2024 to 2034 15. Eastern Industry Analysis 2019 to 2023 and Forecast 2024 to 2034 16. Western Industry Analysis 2019 to 2023 and Forecast 2024 to 2034 17. Southern Industry Analysis 2019 to 2023 and Forecast 2024 to 2034 18. Industry Share Analysis of Top Players 19. Competition Analysis 19.1. Pfizer Inc. 19.2. Bayer AG 19.3. Serum Institute of India 19.4. Intas Pharmaceuticals Limited 19.5. Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) 19.6. Torrent Pharmaceuticals Ltd 19.7. Koye Pharmaceuticals Pvt. Ltd 19.8. Emcure Pharmaceuticals 19.9. Vitabiotics 19.10. Himalaya Global Holdings Ltd. 19.11. Nature's Way Brands 19.12. Bharat Serums and Vaccines Limited (BSV) 19.13. Nordic Naturals 19.14. ZeroHarm 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Menopause Treatment Industry Analysis in India
